22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CDMO), GVB is believed to be one of the largest providers of hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide based on total tonnage. GVB has industry-leading market positions and expertise in all facets of the hemp/cannabis industry, which include: Research and genetics Proprietary cryogenic hemp extraction Refining, conversion, and product formulation technology Leading supplier of Active Pharmaceutical Ingredients (API) Low-cost, scalable manufacturing capabilities Regulatory and compliance expertise Industry trusted high-quality products Current international capabilities GVB’s strengths compliment 22nd Century’s existing upstream and downstream value chains, which includes expertise in cannabinoid receptor science with CannaMetrix, plant research and proprietary genetics through its KeyGene partnership, breeding expertise with Extracts, and cultivation capabilities at Needle Rock Farms.
420 Intel – Marijuana Industry News, 05/15/2022 20:00:00